STA
JSPR icon

Summit Trail Advisors’s Jasper Therapeutics JSPR Stock Holding History

Summit Trail Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,500
Closed -$51.3K – 623
2023
Q4 		$51.3K Hold
6,500
– – ﹤0.01% 545
2023
Q3 		$45.5K Buy
+6,500
New +$79.3K ﹤0.01% 535

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Summit Trail Advisors's JSPR Position: Q1 2024 in Review

Summit Trail Advisors sold out of Jasper Therapeutics (JSPR) in Q1 2024, closing a stake of 6,500 shares — an estimated $51.3K sold.

Summit Trail Advisors first reported a position in JSPR in Q3 2023 and held it in 2 quarters. The position peaked at $51.3K in Q4 2023. 61 funds tracked by Wall St. Rank hold JSPR as of Q1 2024.

  • Summit Trail Advisors reported no remaining Jasper Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Summit Trail Advisors sold 6,500 Jasper Therapeutics shares in Q1 2024, an estimated $51.3K.
  • Summit Trail Advisors first reported a position in Jasper Therapeutics in Q3 2023 and held it in 2 quarters.
  • Summit Trail Advisors's Jasper Therapeutics position peaked at $51.3K in Q4 2023.
  • 61 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2024.

Based on Summit Trail Advisors's 13F filing for Q1 2024, filed 23 Apr 2024.